POLYGYNAX and POLYGYNAX VIRGO (neomycin, polymyxin B, nystatin),

Low clinical benefit in the local treatment of vaginitis caused by sensitive bacteria and non-specific vaginitis

• POLYGYNAX, POLYGYNAX VIRGO and TERGYNAN have Marketing Authorisation in the local treatment of vaginitis caused by sensitive bacteria and non-specific vaginitis.

• A randomised double-blind trial found no significant difference between POLYGYNAX and miconazole administered by vaginal route(GYNO DAKTARIN) in terms of efficacy in the empirical treatment of infectious vaginitis

• For TERGYNAN, no new clinical data have been supplied by the company.